Vasomune Therapeutics is at the 38th J.P. Morgan Healthcare Conference Post author:Shahid Ahmad Post published:January 15, 2020 Post category:Uncategorized Vasomune Therapeutics is currently attending the 38TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California You Might Also Like Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 August 18, 2020 Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy March 25, 2021 The COVID-19 Coronavirus Leads to Acute Respiratory Distress Syndrome (ARDS) March 20, 2020
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 August 18, 2020
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy March 25, 2021